Drugs / BAY3498264
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06659341 | Nov 2024 → Jan 2027 expected | — | Bayer | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY3498264 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06659341 ↗ |
| Action | Inhibit | “by blocking the activity of SOS1 with BAY3498264” NCT06659341 ↗ |
| Route | Oral | “Oral” NCT06659341 ↗ |
| Target | SOS1 | “by blocking the activity of SOS1 with BAY3498264” NCT06659341 ↗ |